Alimera Sciences Inc

Alimera Sciences — Q3 2018 Earnings Presentation

10 slides from Alimera Sciences's earnings presentation, Nov 6, 2018

  1. Slide 1: Third Quarter 2018 Earnings Presentation

    Exhibit 99.2 Third Quarter 2018 Earnings Presentation Tuesday, November 6, 2018

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s anticipated continued momentum through the end of 2018 and into 2019; anticipated addition of an indicat

  3. Slide 3: Third Quarter 2018 Overview

    Third Quarter 2018 Overview +13% $11.1M • Net Revenue of Growth $11.1 Million • Record U.S. end user $9.8M demand of 977 units • Adjusted EBITDA loss improved to $521,000 3Q17 3Q18 Revenue 3 © 2018 Alimera Sciences | NASDAQ: ALIM

  4. Slide 4: U.S. End User Demand

    U.S. End User Demand 1200 977 1000 955 896 851 850 837 827 800 777 788 705 600 533 536 502 467 400 200 167 0 First Quarter Second Quarter Third Quarter Fourth Quarter 2015 2016 2017 2018 4 © 2018 Alimera Sciences | NASDAQ: ALIM

  5. Slide 5: U.S. Distributor Orders and End User Demand

    U.S. Distributor Orders and End User Demand • Historical 1200 inconsistency 1028 1004 1000 980 960977 between distributor 955 896 orders and end user 873 850 864 851 853 827 837 demand* 804 777 788 800 750 705 • 1Q18, 2Q18 and 608 600 3Q18 distributor 536 533 502 501 500 volume was in line 467 460 4

  6. Slide 6: Income Statement ($000's)

    Income Statement ($000’s) Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended September 30,2018 September 30,2017 September 30,2018 September 30,2017 Revenue $11,137 $9,784 $31,856 $26,770 Operating $12,367 $12,570 $38,244 $35,089 Expenses Net Loss ($3,450) ($5,285) ($15,134) (

  7. Slide 7: Third Quarter 2018 Overview

    Third Quarter 2018 Overview +13% $11.1M • Net Revenue of Growth $11.1 Million • Record U.S. end user $9.8M demand of 977 units • Adjusted EBITDA loss improved to $521,000 3Q17 3Q18 Revenue 7 © 2018 Alimera Sciences | NASDAQ: ALIM

  8. Slide 8: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA

    Reconciliation of GAAP Net Loss to NON-GAAP Adjusted EBITDA Alimera believes that the non-GAAP financial information provided in this presentation can assist investors in the overall understanding of its financial performance when considered together with GAAP figures. This presentation contains a d

  9. Slide 9: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA

    Reconciliation of GAAP Net Loss toNON-GAAP Adjusted EBITDA Three Months Ended September 30, Nine Months Ended September 30, ($000’s) 2018 2017 2018 2017 GAAP NetLoss ($3,450) ($5,285) ($15,134) ($14,777) Adjustments to NetLoss Interest Expense, Net and Other $1,211 $1,431 $3,540 $4,152 Provision for

  10. Slide 10: Tuesday, November 6, 2018

    Third Quarter 2018 Earnings Presentation Tuesday, November 6, 2018

Alimera Sciences — Q3 2018 Earnings Presentation on 6ix